Cargando…
Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro
Administration of cetuximab (C-mab) in combination with paclitaxel (PTX) has been used for patients with head and neck squamous cell carcinoma (SCC) clinically. In this study, we attempted to clarify the molecular mechanisms of the enhancing anticancer effect of C-mab combined with PTX on oral SCC c...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503545/ https://www.ncbi.nlm.nih.gov/pubmed/32878053 http://dx.doi.org/10.3390/ijms21176292 |
_version_ | 1783584418726674432 |
---|---|
author | Sawatani, Yuta Komiyama, Yuske Nakashiro, Koh-ichi Uchida, Daisuke Fukumoto, Chonji Shimura, Michiko Hasegawa, Tomonori Kamimura, Ryouta Hitomi-Koide, Masayo Hyodo, Toshiki Kawamata, Hitoshi |
author_facet | Sawatani, Yuta Komiyama, Yuske Nakashiro, Koh-ichi Uchida, Daisuke Fukumoto, Chonji Shimura, Michiko Hasegawa, Tomonori Kamimura, Ryouta Hitomi-Koide, Masayo Hyodo, Toshiki Kawamata, Hitoshi |
author_sort | Sawatani, Yuta |
collection | PubMed |
description | Administration of cetuximab (C-mab) in combination with paclitaxel (PTX) has been used for patients with head and neck squamous cell carcinoma (SCC) clinically. In this study, we attempted to clarify the molecular mechanisms of the enhancing anticancer effect of C-mab combined with PTX on oral SCC cells in vitro. We used two oral SCC cells (HSC4, OSC19) and A431 cells. PTX alone inhibited cell growth in all cells in a concentration-dependent manner. C-mab alone inhibited the growth of A431 and OSC19 cells at low concentrations, but inhibited the growth of HSC4 cells very weakly, even at high concentrations. A combined effect of the two drugs was moderate on A431 cells, but slight on HSC4 and OSC19 cells. A low concentration of PTX enhanced the antibody-dependent cellular cytotoxicity (ADCC) induced by C-mab in all of the cells tested. PTX slightly enhanced the anticancer effect of C-mab in this ADCC model on A431 and HSC4 cells, and markedly enhanced the anticancer effect of C-mab on OSC19 cells. These results indicated that PTX potentiated the anticancer effect of C-mab through enhancing the ADCC in oral SCC cells. |
format | Online Article Text |
id | pubmed-7503545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75035452020-09-23 Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro Sawatani, Yuta Komiyama, Yuske Nakashiro, Koh-ichi Uchida, Daisuke Fukumoto, Chonji Shimura, Michiko Hasegawa, Tomonori Kamimura, Ryouta Hitomi-Koide, Masayo Hyodo, Toshiki Kawamata, Hitoshi Int J Mol Sci Article Administration of cetuximab (C-mab) in combination with paclitaxel (PTX) has been used for patients with head and neck squamous cell carcinoma (SCC) clinically. In this study, we attempted to clarify the molecular mechanisms of the enhancing anticancer effect of C-mab combined with PTX on oral SCC cells in vitro. We used two oral SCC cells (HSC4, OSC19) and A431 cells. PTX alone inhibited cell growth in all cells in a concentration-dependent manner. C-mab alone inhibited the growth of A431 and OSC19 cells at low concentrations, but inhibited the growth of HSC4 cells very weakly, even at high concentrations. A combined effect of the two drugs was moderate on A431 cells, but slight on HSC4 and OSC19 cells. A low concentration of PTX enhanced the antibody-dependent cellular cytotoxicity (ADCC) induced by C-mab in all of the cells tested. PTX slightly enhanced the anticancer effect of C-mab in this ADCC model on A431 and HSC4 cells, and markedly enhanced the anticancer effect of C-mab on OSC19 cells. These results indicated that PTX potentiated the anticancer effect of C-mab through enhancing the ADCC in oral SCC cells. MDPI 2020-08-31 /pmc/articles/PMC7503545/ /pubmed/32878053 http://dx.doi.org/10.3390/ijms21176292 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sawatani, Yuta Komiyama, Yuske Nakashiro, Koh-ichi Uchida, Daisuke Fukumoto, Chonji Shimura, Michiko Hasegawa, Tomonori Kamimura, Ryouta Hitomi-Koide, Masayo Hyodo, Toshiki Kawamata, Hitoshi Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro |
title | Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro |
title_full | Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro |
title_fullStr | Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro |
title_full_unstemmed | Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro |
title_short | Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro |
title_sort | paclitaxel potentiates the anticancer effect of cetuximab by enhancing antibody-dependent cellular cytotoxicity on oral squamous cell carcinoma cells in vitro |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503545/ https://www.ncbi.nlm.nih.gov/pubmed/32878053 http://dx.doi.org/10.3390/ijms21176292 |
work_keys_str_mv | AT sawataniyuta paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro AT komiyamayuske paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro AT nakashirokohichi paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro AT uchidadaisuke paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro AT fukumotochonji paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro AT shimuramichiko paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro AT hasegawatomonori paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro AT kamimuraryouta paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro AT hitomikoidemasayo paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro AT hyodotoshiki paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro AT kawamatahitoshi paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro |